Time to Go Shopping for Healthcare
The decline in equity markets has created opportunities to buy a variety of healthcare stocks at attractive valuations. Insider purchases have...
245 Views
China's FDA Ups Its Game
One of the pharmaceutical industry’s main complaints about China is the extremely slow drug approval process. The approval process in China...
303 Views
QUICKNOTE: H1 Results in Line, R&D Pipeline Expands
3SBio, China's leading biotech company, posted H1 results in line with pre-deal expectations. The recent acquisition of Zhejiang Wansheng broadens...
272 Views
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
352 Views
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
425 Views